Victory Capital Management Inc. boosted its position in Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) by 77.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,357,898 shares of the company's stock after purchasing an additional 591,580 shares during the period. Victory Capital Management Inc.'s holdings in Kura Oncology were worth $18,549,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Great West Life Assurance Co. Can purchased a new stake in Kura Oncology in the third quarter valued at approximately $39,000. Nisa Investment Advisors LLC boosted its position in Kura Oncology by 80.8% in the second quarter. Nisa Investment Advisors LLC now owns 3,290 shares of the company's stock valued at $60,000 after buying an additional 1,470 shares during the last quarter. Denali Advisors LLC boosted its position in Kura Oncology by 71.1% in the second quarter. Denali Advisors LLC now owns 6,500 shares of the company's stock valued at $119,000 after buying an additional 2,700 shares during the last quarter. Amalgamated Bank purchased a new stake in Kura Oncology in the first quarter valued at approximately $123,000. Finally, Principal Financial Group Inc. purchased a new stake in Kura Oncology in the second quarter valued at approximately $198,000.
Get
Kura Oncology alerts:
Kura Oncology Trading Up 3.6 %
Kura Oncology stock opened at $14.60 on Thursday. Kura Oncology, Inc. has a 12 month low of $10.41 and a 12 month high of $19.93. The stock's 50 day simple moving average is $13.63 and its two-hundred day simple moving average is $14.60. The firm has a market cap of $976.70 million, a PE ratio of -7.19 and a beta of 0.90.
Kura Oncology (NASDAQ:KURA – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.04. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.12 EPS for the current year.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Kura Oncology in a research report on Wednesday, October 12th. They issued a "sell" rating on the stock. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.40.
Kura Oncology Company Profile
(Get Rating)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
Featured Articles
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Get Rating).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
